Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea

Pfizer

Status: Completed

Conditions: Advanced Renal Cell Carcinoma

Treatments: Drug: Axitinib

Study type: Observational

Funder types: Industry

Identifiers

NCT02156895

A4061075

Details and patient eligibility

About

The objective of this study is to monitor the usage of INLYTA® in real practice, including the adverse events associated with INLYTA®.

Full description

Investigators can choose any patient who is within the scope of I/E criteria

Enrollment: 111 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed as advanced RCC after failure of one prior systemic therapy.

Exclusion criteria

• Any patient who does not agree that Pfizer or companies working on behalf of Pfizer can use his/her information.
• Patients with hypersensitivity to axitinib or to any other component of INLYTA® .
• Patients under 18.
• Pregnant women.

Trial design

111 participants in 1 patient group

Patients who are using Axitinib

Treatment:

Drug: Axitinib